A method of obtaining a combined vaccine against newcastle disease and infectious laryngotracheitis birds

 

(57) Abstract:

Usage: veterinary Virology. The inventive vaccine is produced by connection vaccinated materials of viruses Newcastle disease and infectious laryngotracheitis birds in one bottle, followed by lyophilization. 3 table.

The invention relates to veterinary Virology, in particular the production of vaccines against Newcastle disease (nd) and infectious laryngotracheitis birds (TLI).

Currently known combined live vaccine firm TAD against NB and infectious bronchitis of poultry [1] and how the combined use of vaccines such as smallpox and NB [2].

The list of living combined vaccines is small, and the use of combined methods of application has its disadvantages: mechanical Union of the two vaccines immediately before vaccination dilutes components, which reduces the effectiveness of vaccination, and the complexity and increase the number of staff in the poultry farms make such a vaccination expensive.

Complex elizaetinsky the situation in some poultry farms requires immunoprotein strain La Sota and TLI from strain VNIIMP - a prototype of the invention.

But this method has its drawbacks: for simultaneous combined vaccination need to know the biological activity of biological products before mixing that in terms of poultry farms are impossible to determine. The violation of the relation between vaccines leads to a decrease in the immune response either to one or to both vaccines, resulting in vaccination becomes ineffective.

The aim of the invention is the creation of a stable combined drug in terms of biofactories with predetermined characteristics and providing tight immunity against NB and TLI.

This objective is achieved in that the vaccine is produced by combining vaccinated materials virus NB from strain La Sota virus and TLI from strain VNIIMP in one bottle at a certain ratio.

In the first stage, prepare macrovu seed is obtained vaccine NB from strain La Sota and against TLI of VNIIMP, further infection of chick embryos and the production of a series of vaccines is conducted according to the "Instructions for the manufacture and control of an experimental batch of virus-vaccine associated dry against Newcastle disease (strain La Sota of Accini against infectious laryngotracheitis birds from strain VNIIMP on December 25, 1980", PM. 2.2 - 4.3. (4, 5).

In the second stage, take the viral suspension, add concentrate virus NB containing an equal number of implanted doses. Doses are determined according to the titer of infectious activity. Then add a protective environment SPLF-20% and the volume was adjusted vaccine in the vial to 4 ml. Then count the total number of viral suspension TLI, concentrate NB and protective environment according to the number of bottles in the series.

After cooking liquid vaccine poured into sterile 4 ml vials, pre-sealed rubber tubes, frozen at a temperature of 50oC and incubated for 2 hours Then dried in the chamber of sublimator and finally sealed, covering with aluminum caps.

After drying, hold the control vaccine on the biological activity of the virus TLI (TU 10.07.032-93 p. 36, PL. 4.5) and virus NB (TU 10.07.032-93 p. 3.5., table. 2,3), statistical calculation performed by the method of reed and turns into a hissing drone. The number of EID501 cm3vaccine virus NB should be not less than 108,6EID50/cm3; virus TLI - 10-5,0EID50/cm3.

Next comes the control vaccine on the physical properties and solubility. (THE 10.07.032-93, PP.3.1.-3.2.).

Check the 1 to 5 chickens.

5 chickens injected with the vaccine intramuscularly in a dose of 0.1 cm diluted 1:10;

10 chickens intranasally 0.05 cm3;

10 chickens intranasally 0.05 cm3diluted 1:50;

10 chickens enterline 5 cm3diluted 1:500;

10 chickens enterline 5 cm3diluted 1:1000.

The feeding vaccines spend two days in the morning before feeding.

See 14 days.

The vaccine is considered harmless if all 45 Chicks will survive.

Immunogenic properties against TLI check through the control of infection of 20 previously vaccinated chickens ocular, intranasal or oral ways. Control contamination spend 15 days after immunization by injection into the trachea 1000 EID50/0.2 cm3previously titrated with chickens virulent virus strain "24A". Observation lead within 10 days. The vaccine is immunogenic, if it protects from disease 16 chickens of 20 vaccinated. The control would have to get to the clinic TLI at least 18 chickens from 20 infected.

Immunogenic properties against NB check in the following way: Chickens, previously vaccinated ocular - 20 goals and 20 control enter to volatise alive and the control die within 8 days.

The finished vaccine is stored at a temperature of(+4) - (+6)oC in a dry dark place for one year.

Conducting a series of experiments to verify the effectiveness shows that the combination vaccine induces 100% of Chicks tight immunity to NB and provides 100% protection from the 1000 LD50virus NB (strain T).

The correlation coefficient of resistance to a virulent virus TLI (strain "24A") is 0.85 - 0.89 and if monopectinate - 0,90 thus, the differences were not statistically significant (table. 1, 2).

When studying reactogenic properties of the combined vaccine experiments show that the 10-fold dose of the vaccine is not reactive and is harmless to chickens 15-17 days of age (table. 3).

These experiments suggest that the use of vaccine strains La Sota virus NB and VNIIMP of ILT virus in the body Chicks not prevent the formation of immunity against NB and TLI, and combined vaccine erectogenic for chickens 15-17 days old and generates intense immunity in ocular and enteral methods of immunization.

Proceeding from the above, we can say that the combination vaccine. the

1. Freesre-dried vaccine for the protection of poultry against infections Bronchitis and Newcastle Disease. Information Miscellanevus Product Data Folder. TAD Pharmazeutisches weerk GMBH D-2190 Cuxhaven 1 P. O. BOX 720. West-Germany.

2. Kachakhidze A. C., Asanidze K., Immunological and economic efficiency associated vaccination of poultry against Newcastle disease (comprehensive vaccination in the intensive livestock sector and its economic efficiency. Proceedings of the Georgian zoovetinstitute, 1983, S. 163-179).

3. Slobodenyuk M. I. and others, the Effectiveness of simultaneous vaccination of chickens aerosol method against Newcastle disease and infectious laryngotracheitis. In the editorial office of the journal "veterinary science", 1993.

A method of obtaining a combined vaccine against Newcastle disease and infectious laryngotracheitis birds, consisting in cooking motroway the seed of vaccines against Newcastle disease from strain La Sota and against infectious laryngotracheitis from strain VNIIMP with subsequent selection of viral suspension of infectious laryngotracheitis, the determination of the number of grafted doses, which are determined according to the titer of infectious activity, add a protective environment SPF-20%, the volume was adjusted vaccines up to 4 ml, poured into sterile vials, frozen, sublimate and the

 

Same patents:

The invention relates to the field of veterinary Virology, namely, the vaccine against Aujeszky's disease for oral immunization of pigs and can be used for vaccination as domestic and wild animals

The invention relates to medicine and relates to the diagnosis of cytomegalovirus /CMV/ infection

The invention relates to veterinary medicine and, in particular, to the treatment of infectious diseases of animals and humans, accompanied by encephalitis

The invention relates to biotechnology, in particular for the associated vaccine used for specific prophylaxis of viral enteritis, botulism, Pseudomonas and distemper

The invention relates to and veterinary medicine and can be used for the prevention of canine distemper
The invention relates to the field of Virology, namely the use of pigs to obtain specific sera and whey products for immunoprophylaxis and immunotherapy of canine distemper

The invention relates to veterinary Virology, in particular to a vaccine against Newcastle disease and method of its use

The invention relates to veterinary Virology and can be used at the enterprises of biological industry for the production of specific prophylaxis of viral hepatitis and distemper

FIELD: veterinary medicine.

SUBSTANCE: vaccine has antigenic material produced from La-Sota strain reproduced in 9-10 days old SPF-hen embryos having infectious activity of at least 9.7 lg EID50/cm3 and hemagglutination activity equal to at least 1:512, protective medium and adjuvant of thymogen taken in effective proportions. The protective medium comprises 20% lactalbumin hydrolyzate solution and degreased milk in 1:5 proportion. The vaccine is produced by mixing its ingredients and with following preparation lyophilization. Ready vaccine is dry porous mass of light yellow color. The vaccine is applicable for carrying out specific prophylaxis. The vaccine is introduced as spray at a dose of 1 cm3/head.

EFFECT: high antigenic and immunogenic activity; no adverse side effects.

7 cl, 8 tbl

FIELD: medicine, in particular uses of viruses for cell elimination.

SUBSTANCE: invention relates to uses of viruses capable of reducing undesired cells in ex vivo mixtures of normal marrow or peripheral blood cells and tumor cells, such as leucosis or lymphoma cells due to interaction of abovementioned mixture with vesicular stomatitis virus. Invention also relates to method for malignant tumor treatment in mammalian. Claimed method includes sampling of mammalian marrow or peripheral blood cells; interaction of said cells ex vivo with vesicular stomatitis virus; mieloablative therapy; and transplantation of purified hematopoietic cells into mammalian. In another embodiment invention relates to method for malignant tumor treatment in mammalian having transplant of marrow or peripheral blood stem cells. Said method includes interaction ex vivo of collected transplant cell with vesicular stomatitis virus and administration of these purified cells in mammalian. Method of present invention makes it possible to reduce risk of malignant tumor backset in mammalian with transplanted hematopoietic cells.

EFFECT: new agent for elimination of marrow or peripheral blood tumor cells.

12 cl, 4 ex, 3 tbl

FIELD: gene engineering, virology, veterinary.

SUBSTANCE: invention relates to DNA-vaccine against canine distemper virus (CDV). Said vaccine includes at least one DNA-plasmid and cationic lipid containing ammonium salt of formula represented in claim 1 as adjuvant. DNA-plasmid also contains and expresses in host-cells nucleotide sequence encoding CVD immunogene. Nucleotide sequence contains deletion of site, encoding transmembrane domain. Polyvalent vaccine, containing such DNA-vaccine and immunogenic composition containing such DNA-plasmid also are disclosed.

EFFECT: new vaccine for vaccination of dogs against CDV.

41 cl, 28 dvg, 3 tbl, 14 ex

FIELD: veterinary virology.

SUBSTANCE: the suggested vaccine contains a virus-containing material obtained at combined cultivation of avian smallpox virus upon cell culture of hen's fibroblasts "VGNKI-3" strain and virus of Newcastle disease "M-VNII VV&M" strain. Virus content in cell culture corresponds to 0.02-0.04 and 0.02-0.08 TCD/cell, correspondingly. The suggested virus vaccine is of high immunogenicity.

EFFECT: higher efficiency of vaccine application.

1 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with heating hens' embryos with light of fluorescent lamp DNESG-500, wave length being 630-650 nm, average dosage at eggs surface being 23.1 erg at exposure of 5 min, irradiation with He-Ne laser LHN-104, wave length being 632.8 nm, power density of optic flow at eggs surface being 50 mW/sq. cm, with mercury-quartz lamp DRT-400, wave length being 400/185 nm, average dosage at eggs surface being 20 mErg/h out of "Bor-74 VGNKI" strain. Light treatment of embryos in the same mode and poultry immunization should be combined with eggs disinfection from all sides with two bactericidal lamps BUV-15, wave length being 254/800 nm, nominal power at eggs surface of 15 W and three bactericidal lamps BUV-30, wave length being 254/800 nm, nominal power of 30 W at exposures per 3 min. And poultry light treatment in the same mode should be carried out before incubation on the 6th, 12th, 18th d of embryos development and in incubated day-long chickens. The innovation prolongs survival rate in broilers grown under industrial conditions being unfavorable on Newcastle disease.

EFFECT: higher efficiency.

3 tbl

FIELD: veterinary science, poultry science.

SUBSTANCE: the present innovation deals with pre-incubation treatment of hen embryos with the light of fluorescent lamp DNESG-500 at wave length of 630-650 nm, average dosage at egg surface being 23.1 erg at exposure of 17 sec, with He-Ne laser LHN-104 at wave length of 632.8 nm, power density of optic flow at egg surface being 50 mW/sq. cm·sec at exposure of 3 sec, with mercury-quartz lamp DRT-400 at wave length of 400/185 nm, average dosage at egg surface being 20 merg/h at exposure of 3 min. Moreover, such treatment should be fulfilled before laying for incubation on the 6th, 12th, 18th d of incubation and in daily chickens 4-fold at 5-min-long interval. Then comes disinfection from all the sides with two bactericidal lamps BUV-15 at wave length of 254/800 nm, nominal power at egg surface being 15 W at exposure per 5 sec and with three bactericidal lamps BUV-30 at wave length of 254/800 nm, nominal power at egg surface being 30 W at exposure of 17 sec. Incubated broiler chickens should be immunized with the vaccine of "Bor-74 BGNKI" strain. The innovation enables to increase specific resistance to Newcastle disease in poultry.

EFFECT: higher efficiency.

3 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to methods of self-specific T-cell vaccine production. Self-specific T-cell vaccine for disseminated sclerosis treatment includes attenuated T-cells which are reactive relative to one or several epitopes, yet SEQ ID NOS: 1-6 contain these epitopes. Invention is intended for treatment of autoimmune diseases, such as disseminated sclerosis or rheumatoid arthritis using self-specific T-cell vaccines. Besides, invention provides diagnostics of diseases associated with T-cells. Advantage of this invention implies that it can be applied for production of T-call vaccines with heterogenous gene VR-Dp-JR to take into consideration clonal shift if self-reactive T-cells.

EFFECT: method has improved efficiency.

10 cl, 7 ex, 2 dwg

FIELD: medicine; biotechnologies.

SUBSTANCE: vaccine contains virus material from "La-Sota" strain, saccharose, enzymatic peptone, casein, aerosil AM-1-300 and resin KB-4P-2. At that virus material from "La-Sota" strain used in vaccine is suspension from whole hen's eggs with developed 12-13-day embryos infected with culture of "La-Sota" strain at 9-10 day of their incubation. Vaccine also additionally contains α-tocopherol with the following ratio of components, wt %: suspension from whole hen's eggs with developed 12-13-day embryos infected with culture of "La-Sota" strain at 9-10 day of their incubation - 10.73-12.47, saccharose - 4.16-4.60, enzymatic peptone - 2.50-3.06, casein - 0.83-1.53, α-tocopherol - 0.04-0.08, aerosil AM-1-300 - 1.00-2.00, resin KB-4P-2 - the rest.

EFFECT: high immunogenicity, harmlessness for bird and ecological safety for servicing personnel.

4 tbl, 5 ex

FIELD: veterinary science.

SUBSTANCE: invention relates to veterinary virology. Under the method proposed one grows a vaccine strain of "La-Sota" virus on chicken embryos. After that pearl-barley, heat treated, is mixed with allantoic fluid containing the vaccine strain, soaked with a stabiliser solution represented by a mixture of 40% peptone and 8% lactose, frozen at a temperature of minus 5020C during 8-10 hours and lyophilised during 30-32 hours.

EFFECT: proposed method enables production of an oral application vaccine for bird immunisation that is characterised by high immunological efficiency and storage stability.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely oncology and can be used in treatment of tumours. The method involves introduction of an autologous vaccine representing heat-shock proteins recovered from tumour tissue of the patient in a complex with tumour antigens. Thus treatment with the autologous vaccine is preceded with introduction of an oncolytic attenuated Newcastle disease virus as an adjuvant.

EFFECT: application of the invention allows improving clinical effectiveness in tumours ensured by formation of a vaccine-induced specific immune response against tumour and additional stimulation of nonspecific immunity combined with cytolytic activity of the adjuvant.

2 cl, 4 dwg, 4 ex

Up!